Central Lab Market

Laboratories Work with Logistics Partners to Maintain Business Continuity During COVID-19 Crisis

Companies in the central lab market have been under scrutiny for minimizing potential disruptions to logistical movements of human samples and potential supply issues for clinical kits during the ongoing COVID-19 pandemic. LabConnect - a preeminent provider of central laboratory support services is increasing efforts to closely work with its logistics providers and courier partners to implement alternative transportation solutions, owing to increased cost of transporting supplies.

Stakeholders in the central lab market are collaborating with network laboratories to assess the current coronavirus situation and plan its potential impact on lab testing services. Laboratory vendors are closely monitoring and updating their business continuity plans in severely affected COVID-19 regions. Stakeholders are working closely with their staff to monitor subject compliance.

Request a sample to get extensive insights into the Central Lab Market 

Additional Training of Non-physician Medical Specialists Accelerates Lab Procedure Outcomes

The central lab market is estimated to surpass US$ 4.1 Bn mark by 2030. However, central lab stakeholders are posed with many challenges, such as time consuming processes, since several sites samples need to reach one lab and may take several days. Hence, central labs are now sharing this responsibility with local lab facilities whilst increasing R&D to adopt processes that accelerate their lab procedures.

On the other hand, the German healthcare system in the central lab market poses issue in invoicing medical services to non-physician medical specialists in hospitals due to the scarcity of medical professionals. Hence, the German Society for Laboratory Medicine (DGKL) is increasing efforts to provide additional training in a master program in laboratory medicine aimed at medical professionals to facilitate invoicing for lab services in hospitals.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Encrypted Connections Help Secure Real-time Laboratory Information Data Portals

The central lab market is slated to register a favorable CAGR of ~6% during the forecast period. Companies such as the Eurofins Central Laboratory is making the use of its real-time laboratory information data portal called Fetch for investigator sites and sponsors to have access to the data for their user accounts. Lab professionals are increasing efforts to provide 24/7 secured access to clinical trial information and authorized data reports. Companies are collaborating with software developers to secure laboratory information data portals with encrypted connections.

Companies Deploy AI, Automation, Blockchain Technologies to Support Central Labs

A plethora of technological and software innovations are storming the central lab market. Q2 Solutions-a global clinical trial laboratory services organization is supporting central labs with innovations such as artificial intelligence (AI) protocol reading, sample & consent tracking, and next-gen flow cytometry result reporting automation, among others.

Direct to patient kit shipments, blockchain for sample tracking, and electronic histology & pathology reports are benefitting stakeholders in the central lab market. They are unlocking growth opportunities in supporting decentralized virtual trials innovation. Thus, companies are partnering with mobile nurse and phlebotomy companies to enable in-home specimen collection from individuals and patients alike.

Compliance with CAP, CLIA Standards Boosts Credibility of Stakeholders

Efficient service and quality data without compromise has become important for companies in the central lab market. PPD Laboratories’ Central Lab is gaining recognition in Asia, Europe, and North America for its global laboratory assay standardization survey i.e. GLASS, which is harmonizing processes across locations. Companies are increasing efforts to streamline auditing, deviation management, and standard operating procedures.

Companies in the central lab market are committing to operational excellence in order to comply with the global standards as suggested by the College of American Pathologists (CAP), the Clinical Laboratory Improvement Amendments (CLIA), and the likes. As such, real-time central lab database management platforms are becoming a recurring market trend, as it can be automatically integrated with the patient or medical data of a clinical trial management system.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Central Lab Market

Analysts’ Viewpoint

Companies in the central lab market are increasing efforts to implement home visit testing for several COVID-19 research studies and provide high quality support to logistics courier partners. Investigator site portals are providing intuitive and interactive tools for central lab sites in order to manage register samples, subject enrollment, order collection kits, etc. Electronic lab requisition reduces the risk of sample loss by enabling a chain of custody before the sample leaves the clinic. However, study teams face complexities such as working with niche laboratories to evaluate decentralized clinical trial designs. In order to overcome these challenges, companies should transition toward AI, blockchain, and automation technologies in laboratory trials management systems and for sample tracking.